Keywords: Arena Pharma, Temanogrel, Ildong Pharma, South Korea, Cardiovascular conditions

Arena Pharma licenses temanogrel to Ildong Pharma for South Korea

Article | 28 November 2012

Print This

The USA’s Arena Pharmaceuticals (Nasdaq: ARNA) has entered into a co-development and license agreement with South Korea’ ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in